Research progress of monoclonal antibody in the treatment of lung cancer
DOI:
https://doi.org/10.54097/9p35ff48Keywords:
monoclonal antibody; lung cancer; immunotherapy.Abstract
The largest cause of cancer-related deaths is lung cancer. Conventional therapies like chemotherapy, surgery and radiation therapy have been widely used in treating cancer including lung cancer. However, the fact is that these conventional therapies may generate severe adverse effects. For example, they are lack of specificity, they could not treat the target tissue specifically. When processing these conventional treatments, adjacent normal cells and tissues may be harmed. With this kind of problem in treating lung cancer, more and more therapeutic drugs and therapies are being develop to reduce such problems. Monoclonal antibody treatment is an example. Since the concept of magic bullet had been introduced by Pual Ehrlich, scientists have been inspired to conduct further and deeper research into monoclonal antibody treatment. In this concept, antibodies are said to be magic bullets since they are useful tool to treat foreign cells. Since then, scientists had been devoting themselves to the development of monoclonal antibodies. These days several monoclonal antibodies are FDA approved. Since monoclonal antibodies work through various mechanisms, it plays an important role in cancer therapies. One monoclonal antibody is specific to only one type of antigen and it works by trigger the immune system. Monoclonal antibodies would become the focus of future research.
Downloads
References
Anagnostopoulos AK, et al. Radiomics in Lung Cancer: Basic Principles and Initial Clinical Results. Cancers. 2022; 14(7):1657.
Alberto Ruano-Raviña, et al. Lung cancer symptoms at diagnosis: results of a nationwide registry study, 2020, e001021,
Castelli, M. S., et al. (2019). The Pharmacology and Therapeutic Applications Of Monoclonal Antibodies. Pharmacology Research &Amp; Perspectives, 6(7).
Yoann Le Basle, et al. Physicochemical Stability of Monoclonal Antibodies, Journal of Pharmaceutical Sciences, 2020, 169-190,
Li T. Comparative analysis and development forecast of domestic and global monoclonal antibody drug industry [D]. Shandong University, 2015.
Aldarouish, et al. “Trends and advances in tumor immunology and lung cancer immunotherapy.” Journal of experimental & clinical cancer research : CR vol. 35,1 157. 29 Sep. 2016
Zhou Xiaochun, et al. PD-1The effect of anti-PD-1 intratumoral injection on lung cancer in mice[J].Immunological Journal, 2021,37(03): 270-276.
Kobayashi S, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–92.
Sweis RF, et al. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 2016 Feb 26;8(2):e513.
Chen Pengtao&Ai Yan (2022). Clinical efficacy of bevacizumab combined with thoracic perfusion chemotherapy in the treatment of non-small cell lung cancer with malignant pleural effusion Journal of Clinical Rational Drug Use.
Song Wei, et al. (2023). Study on the efficacy and safety of nituzumab combined with paclitaxel and carboplatin in the treatment of advanced lung cancer Journal of Medical Forum (05), 84-87
Wang, Kai et al. “An update in clinical utilization of photodynamic therapy for lung cancer.” Journal of Cancer vol. 12,4 1154-1160. 2021
[16]Xie Yangyang, et al. Clinical application and drug resistance optimization strategy of antibody conjugated drug[J].Drugs & Clinic,2021,36(07):1520-1526.
]Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics[J]. Bioscience reports, 2015, 35(4): e00225.
Merle, Geoffrey MD; et al. , “Antibody Drug Conjugates in Lung Cancer” The Cancer Journal p 429-435, 2022
Riudavets M, et al. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations[J]. ESMO open, 2021, 6(5): 100260.
Wnag Jia, et al. A novel HER2-targeting antibody-drug conjugate: trastuzumab deruxtecan[J].Chinese Journal of New Drugs and Clinical Remedies,2021,40(02):104-108.
Kroschinsky, Frank et al. “New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.” Critical care (London, England) vol. 21,1 89. 2017
Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
Laffleur, Brice et al. “Production of human or humanized antibodies in mice.” Methods in molecular biology (Clifton, N.J.) 901: 149-59.
José M.P.L., et al. (2021) Antibodies targeting enzyme inhibition as potential tools for research and drug development. Biomolecular Concepts 12:1, pages 215-232.
Wang, H., et al. (2008) Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother 57, 677–684.
J Clin Oncol 23:1538-1547. by American Society of Clinical Oncology
Bin Yang, et al. Humanized design of variable region of antibody HAb18 based on surface remodeling method [J]. Science Technology and Engineering,2007(14):3378-3382.
Bennett, N.R., et al. Improving de novo protein binder design with deep learning. Nat Commun 14, 2625 (2023).
Reichert, Janice M. “Antibodies to watch in 2013: Mid-year update.” mAbs vol. 5,4 (2013): 513-7.
Hélène Kaplon, et al. (2020) Antibodies to watch in 2020, mAbs, 12:1
Shoae M, et al. An overview of the current status of engineered therapeutic monoclonal antibodies. Int. Pharm. Acta. 2019;2(1): e9.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







